GEN Biotech Events

GEN Weekly Highlights 

March 9–March 15, 2012   
NewsCenter Application Notes
Insight & Intelligence™ Helpful Links
Webinars View email in a browser
Online Exclusives Forward to a Colleague


Ideal for the transfection of cells in 3D cell culture, the new 3D Transfection System combines the technologies of Reinnervate's alvetex® 3D Cell Culture Plates and Mirus Bio's TransIT®-3D Transfection Reagent that enables scientists to gain a deeper insight into the complexities of cell function.



March 15, 2012, 08:26 AM EST
Shire to Buy FerroKin for $100M Cash to Acquire Phase II Iron Chelator

FerroKin projects once-daily oral tablet could reach the market by 2016.

March 15, 2012, 08:55 AM EST
GW Pharma to Receive $15.7M from Almirall for Expanded Sativex Marketing Rights

Almirall gains MS drug license in Mexico and will pay GW less for Sativex supply.

March 15, 2012, 09:01 AM EST
Biogen Idec Takes Option to MAKScientific MS Program

Preclinical-stage firm is developing drugs that modulate cannabinoid pathways.

March 15, 2012, 09:12 AM EST
Immune Mouse that Fully Recapitulates Individual Human Immune System Developed

Model will enable study of autoimmune disorders and facilitate development of personalized therapies.

March 14, 2012, 09:13 AM EST
ProNAi to Couple DNAi Therapies with Marina's Liposomal Delivery System

Marina is entitled to $14 million in total fees per gene target plus royalties.

March 13, 2012, 08:53 AM EST
OriGene Takes Over Pathology Reagent Company Zhongshan Golden Bridge Biotechnology

ZsBio was established in 1993 and is based in Beijing.

March 13, 2012, 08:57 AM EST
Pfizer, Biocon End Insulin Biosimilars Partnership

Firms cite differing priorities that favor independence.

March 13, 2012, 09:31 AM EST
Agennix Contracts DSM for Commercial Supply of a Dendritic Cell Mediated Immunotherapy

Talactoferrin is in Phase III studies against non-small-cell lung cancer.

March 12, 2012, 09:30 AM EST
Immunovaccine, Weill Cornell Medical College to Progress Anticocaine Vaccine

Firm's adjuvanting technology will be coupled with Cornell's vaccine.

March 12, 2012, 09:55 AM EST
EMD Millipore, Centre for Commercialization of Regen Med to Optimize Large-Scale Stem Cell Cultivation

Monitoring and control methodology will be developed for EMD's Mobius CellReady bioreactor.

View more news updated daily on the GEN website.

Insight & Intelligence
Insight & Intelligence

Will Roche Really Drop Illumina and Seek out Another Sequencing Firm?

Oxford Nanopore and PacBio both have exciting technologies, but Illumina remains market leader.     more I&Is

GEN Article from Latest Issue

RNA Advances Reshape Prevailing Wisdom   March 15 issue


Featured GEN Webinars
GEN Webinar

Illuminating Pathways for Disease Research

Broadcast Date: Available on Demand: Original Broadcast Date — March 07, 2012
Sponsored by: Agilent Technologies


   All GEN Webinars

Online Exclusives


How much effect do you think the Euro crisis will have on the U.S. biopharma industry?   more polls

Application Note Library

More Application Notes

More at GEN
New Products GEN Magazine Send Feedback Forward to Colleague

Advertising l Editorial l Business and Partnership Opportunities
Subscription Center l Unsubscribe l About GEN

Follow GEN on Linkedin Follow GENbio on Twitter! Follow GEN on Facebook! Watch GEN on You Tube Subscribe to an RSS feed!